Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
Robert FoersterDaniel Rudolf ZwahlenAndre BuchaliHongjian TangChristina SchroederPaul WindischErwin VuSati AkbabaTilman BostelTanja SpraveConstantinos ZamboglouThomas ZilliJean-Jacques StelmesTejshri TelkhadeVedang MurthyPublished in: Cancers (2021)
At this point, SBRT with or without pelvic ENI cannot be considered the standard of care in HR PCA, due to missing level 1 evidence. Treatment may be offered to selected patients at specialized centers with access to high-precision RT. While concomitant ADT is the current standard of care, the necessary duration of ADT in combination with SBRT remains unclear. Ideally, all eligible patients should be enrolled in clinical trials.
Keyphrases
- prostate cancer
- radiation therapy
- palliative care
- clinical trial
- end stage renal disease
- healthcare
- chronic kidney disease
- quality improvement
- ejection fraction
- newly diagnosed
- prognostic factors
- affordable care act
- peritoneal dialysis
- rectal cancer
- squamous cell carcinoma
- patient reported outcomes
- randomized controlled trial
- health insurance
- phase iii